Neoantigens and Therapeutic Vaccines for Cancer (NeoVaCan)

NEOANTIGENS AND THERAPEUTIC VACCINES FOR CANCER (NEOVACAN)

Principal Investigator: Leticia De Mattos-Arruda

Presentation

Our group conducts research using multi-omics and immune characterization of solid tumours and liquid biopsies at several layers, with the goal of taking cancer patient therapy towards personalization and achieving a better understanding of tumour genomic and immune heterogeneity.

With IrsiCaixa Cell Virology and Immunology (VIC) group and Barcelona Supercomputing Center teams, our group is working on co-developing a therapeutic neoantigen cancer vaccine for clinical application. As one of the two pillars of cancer vaccine development at IrsiCaixa, our group will coordinate the clinical side, translating next-generation sequencing-guided and experimental analyses of neoantigen prediction to therapeutic benefits for patients with cancer.

Keywords: cancer, genomics, neoantigens, bioinformatics, biomarkers, vaccine
Principal Investigator

Leticia De Mattos-Arruda

Dr Leticia De Mattos-Arruda, MD, PhD is a physician-scientist medical oncologist who joined IrsiCaixa as principal investigator of the Neoantigens and Therapeutic Personalized Cancer Vaccines (NeoVaCan) group. ...

Curriculum

Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

'La Caixa' Foundation Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

Member of:

Cerca

In cooperation with: